[HTML][HTML] Pathogenicity of SARS-CoV-2 Omicron (R346K) variant in Syrian hamsters and its cross-neutralization with different variants of concern

S Mohandas, PD Yadav, G Sapkal, AM Shete… - …, 2022 - thelancet.com
Summary Background SARS-CoV-2 Omicron variant is rampantly spreading across the
globe. We assessed the pathogenicity and immune response generated by BA. 1.1 sub …

[HTML][HTML] Reduced pathogenicity of the SARS-CoV-2 omicron variant in hamsters

K McMahan, V Giffin, LH Tostanoski, B Chung… - Med, 2022 - cell.com
Background The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron
(B. 1.1. 529) variant has proven to be highly transmissible and has outcompeted the Delta …

[HTML][HTML] Clinical and experimental evidence suggest omicron variant of SARS-CoV-2 is inherently less pathogenic than delta variant independent of previous immunity

R Thiruvengadam, ZA Rizvi, S Raghavan… - European journal of …, 2023 - Springer
Objectives To study clinical disease outcomes in both human and animal models to
understand the pathogenicity of omicron compared to the delta variant. Methods In this cross …

Characteristics of the SARS-CoV-2 Omicron (B. 1.1. 529) variant and emerging impact on global public health

M Rabiul Islam, W Nasreen, R Anjum… - Clinical …, 2022 - journals.sagepub.com
The discovery of the SARS-CoV-2 Omicron (B. 1.1. 529) variant has sparked alarm globally
because of its rapid rate of infection and trespassing acquired immunity due to vaccination …

The SARS-CoV-2 Omicron (B. 1.1. 529) variant exhibits altered pathogenicity, transmissibility, and fitness in the golden Syrian hamster model

S Yuan, ZW Ye, R Liang, K Tang, AJ Zhang, G Lu… - BioRxiv, 2022 - biorxiv.org
The newly emerging SARS-CoV-2 Omicron (B. 1.1. 529) variant first identified in South
Africa in November 2021 is characterized by an unusual number of amino acid mutations in …

[HTML][HTML] The omicron (B. 1.1. 529) SARS-CoV-2 variant of concern does not readily infect Syrian hamsters

R Abdelnabi, CS Foo, X Zhang, V Lemmens, P Maes… - Antiviral research, 2022 - Elsevier
The emergence of SARS-CoV-2 variants of concern (VoCs) has exacerbated the COVID-19
pandemic. End of November 2021, a new SARS-CoV-2 variant namely the omicron (B. 1.1 …

[HTML][HTML] Infection, pathology and interferon treatment of the SARS-CoV-2 Omicron BA. 1 variant in juvenile, adult and aged Syrian hamsters

L Yuan, H Zhu, P Chen, M Zhou, J Ma, X Liu… - Cellular & Molecular …, 2022 - nature.com
The new predominant circulating SARS-CoV-2 variant, Omicron, can robustly escape
current vaccines and neutralizing antibodies. Although Omicron has been reported to have …

[HTML][HTML] Challenges of SARS-CoV-2 Omicron Variant and appropriate countermeasures

W Shao, W Zhang, X Fang, D Yu, X Wang - Journal of Microbiology …, 2022 - Elsevier
Abstract The Omicron (B. 1.1. 529) variant was first reported in South Africa and rapidly
spread worldwide in early November 2021. This caused panic in various countries, so it is …

[HTML][HTML] The 2022 World Health Organization (WHO) priority recommendations and response to the Omicron variant (B. 1.1. 529) of SARS-CoV-2

DV Parums - … Science Monitor: International Medical Journal of …, 2022 - ncbi.nlm.nih.gov
The omicron variant of SARS-CoV-2, B. 1.1. 529, was included in the World Health
Organization (WHO) list of variants of concerns (VOC) on 26 November 2021. Within only …

[HTML][HTML] Attenuated replication and pathogenicity of SARS-CoV-2 B. 1.1. 529 Omicron

H Shuai, JFW Chan, B Hu, Y Chai, TTT Yuen, F Yin… - Nature, 2022 - nature.com
Abstract The Omicron (B. 1.1. 529) variant of SARS-CoV-2 emerged in November 2021 and
is rapidly spreading among the human population. Although recent reports reveal that the …